Signaling pathway activated during apoptosis of the prostate cancer celt line LNCaP: Overexpression of caspase-7 as a new gene therapy strategy for prostate cancer

Cancer Research

Volumn 59, Issue 2, 1999, Pages 382-390

  Marcelli, Marco ^a   Cunningham, Glenn R ^a   Walkup, Margaret ^a   He, Zening ^a   Sturgis, Lydia ^d   Kagan, Carolina ^d   Mannucci, Roberta ^b   Nicoletti, Ildo ^b   Teng, BaBie ^c   Denner, Larry ^d  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF PERUGIA   (Italy)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^d TEXAS BIOTECHNOLOGY CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; CASPASE 3; CASPASE 7; CYTOCHROME C; ONCOPROTEIN; PROTEIN BCL 2; STAUROSPORINE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; ENZYME ACTIVATION; ENZYME INHIBITION; GENE THERAPY; HUMAN; IMMUNOBLOTTING; MALE; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

APOPTOSIS; BUTYRATES; CASPASE 2; CASPASE 3; CASPASE 7; CASPASES; CYTOCHROME C GROUP; ENZYME ACTIVATION; GENE THERAPY; HUMANS; MALE; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; STAUROSPORINE; TUMOR CELLS, CULTURED;

EID: 0033556005     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Parker, S., Tong, T., Bolden, S., and Wingo, P. Cancer statistics, 1997. CA Cancer J. Clin., 47: 5-27, 1997.
2. Santen, R. J. Endocrine treatmenl of prostate cancer. J. Clin. Endocrinol. Metab., 75: 685-689, 1992.
3. Kyprianou, N., English, H., and Isaacs, J. Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res., 50: 3748-3753, 1990.
4. Isaacs, J., and Coffey, D. Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation as studied in the Dunning R-3327 H adenocarcinonia. Cancer Res., 41: 5070-5075, 1981.
5. Isaacs, J., Lundmo, P., Berges, R., Martikainen, P., Kyprianou, N., and English, H. Androgen regulation of programmed cell death of normal and malignant prostatic cells. J. Androl., 13: 457-464, 1992.
6. Kyprianou, N., and Isaacs, J. T. "Thymineless" death in androgen-independent proslatic cancer cells. Biochem. Biophys. Res. Commun., 165: 73-81, 1989.
7. Marcelli, M., G. Cunningham, S. Haidacher, S. Padayatty, L. Sturgis, C. Kagan, and L. Denner. Caspase-7 is activated during lovastatin-induced apoptosis of the prostate cancer cell line LNCaP. Cancer Res., 58: 76-83, 1998.
8. Raffo, A., Perlman, H., Chen, M-W., Day, M., Streitman, J., and Buttyan, R. Overexpression of bcl-2 protects cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res., 55: 4438-4445, 1995.
9. Bossy-Wetzel, E., Newmeyer, D. D., and Green, D. R. Mitochondrial cytochrome c release in apoptosis occurs upstream of DEVD-specific caspase activation and independently of mitochondrial transmembrane depolarization. EMBO J., 17: 37-49, 1998.
10. Duan, H., Chinnaiyan, A. M. Hudson, P. L., Wing, J. P., He, W. W., and Dixit, V. M. ICE-LAP3, a novel mammalian homologue of the Caenorhabditis elegans cell death protein Ced-3 is activated during Fas- and tumor necrosis factor-induced apoptosis. J. Biol. Chem., 271: 1621-1625, 1996.
11. Teng, B., Blumenthal, S., Forte, T., Navatnam, N., Scott, J., Gotto, A., and Chan, L. Adenovirus-mediated gene transfer of rat apolipoprotein B mRNA-editing protein in mice virtually eliminates apolipoprotein B-100 and normal low density lipoprotein production. J. Biol. Chem., 269: 29395-29404, 1994.
12. Smith, T., Mehaffey, M., Kayda, D., Saunders, J., Yei, S., Trapnell, B., McClelland, A., and Kaleko, M. Adenovirus-mediated expression of therapeutic plasma levels of human factor IX in mice. Nat. Genet., 5: 397-402, 1993.
13. McGrory, W., Bautista, D., and Graham, F. A simple technique for the rescue of early region 1 mutations into infectious human adenovirus type 5. Virology, 163: 614-617, 1988.
14. Graham, F., Smiley, J., Russel, W., and Norin, R. Characteristics of a human cell line transformed by human adenovirus type 5. J. Gen. Virol., 36: 59-72, 1977.
15. Kluck, R., Bossy-Wetzel, E., Green, D., and Newmeyer, D. The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science (Washington DC), 275: 1132-1136, 1997.
16. Yang, J., Liu, X., Bhalla, K., Kim, C., Ibrado, A., Cai, J., Peng, T-I., Jones, D., and Wang, X. Prevention of apoptosis by BCL-2: release of cytochrome c from mitochondria blocked. Science (Washington DC), 275: 1129-1132, 1997.
17. Thomberry, N. A., Rano, T. A., Peterson, E. P., Rasper, D. M., Timkey, T., Garcia-Calvo, M., Houtzager, V. M., Nordstrom, P. A., Roy, S., Vaillancourt, J. P., Chapman, K. T., and Nicholson, D. W. A combinatorial approach defines specificities of members of the caspase family and granzyme B: functional relationships estab-lished for key mediators of apoptosis. J. Biol. Chem., 272: 17907-17911, 1997.
18. Kaufmann, S., Desnoyers, S., Ottaviano, Y., Davidson, N., and Poirier, G. Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res., 53: 3976-3985, 1993.
19. Liu, X., Zou, H., Slaughter, C., and Wang, X. DFF, a heterodimeric protein that functions downstream of caspasc-3 to trigger DNA fragmentation during apoptosis. Cell. 89: 175-184, 1997.
20. Enari, M., Sakahira, H., Yokoyama, H., Okawa, K., Iwamatsu, A., and Nagata, S. A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature (Lond.), 391: 43-50, 1998.
21. Sakahira, H., Enari, M., and Nagata, S. Cleavage of CAD inhibitor in CAD activation and DNA degradation during apoptosis. Nature (Lond.), 39: 96-99, 1998.
22. Zhao, X., Gschwend, J. E., Powell, C. T., Foster, R. G., Day, K. C., and Day, M. L. Retinoblastoma protein-dependent growth signal conflict and caspase activity are required for protein kinase C-signaled apoptosis of prostate epithelial cells. J. Biol. Chem., 272: 22751-22757, 1997.
23. Ruegg, U. T., and Burgess, G. M. Staurosporine, K-252 and UCN-01: potent but nonspecific inhibitors of protein kinases. Trends Pharmacol. Sci., 10: 218-220, 1989.
24. Lassota, P., Singh, G., and Kramer, R. Mechanism of topoisomerase II inhibition by staurosporine and other protein kinase inhibitors. J. Biol. Chem., 271: 26418-26423, 1996.
25. Liu, X., Kim, C., Yang, J., Jemmerson, R., and Wang, X. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell, 86: 147-157, 1996.
26. Hengarter, M. CED-4 is a stranger no more. Nature (Lond.), 388: 714-715, 1997.
27. Zou, H., Henzel, W., Liu, X., Lutschg, A., and Wang, X. Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell, 90: 405-413, 1997.
28. Duan, H., Orth, K., Chinnaiyan, A., Poirier, G., Froelich, C., He, W-W., and Dixit, V. ICE-LAP6, a novel member of the ICE/Ced-3 gene family, is activated by the cytotoxic T cell protease granzyme B. J. Biol. Chem., 271: 16720-16724, 1996.
29. Srinivasula, S., Fernandez-Alnemri, T., Zangrilli, J., Robertson, N., Armstrong, R., Wang, L., Trapani, J., Tomaselli, K., Litwack, G., and Alnemri, E. The Ced-3/ Interleukin 1β converting enzyme-like homolog Mch6 and the lamin-cleaving enzyme Mch-2α are substrates for the apoptotic mediator CPP32. J. Biol. Chem., 271: 27099-27106, 1996.
30. Li, P., Nijhawan, D., Budihardjo, I., Srinivasula, S. M., Ahmad, M., Alnemri, E. S., and Wang, X. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell, 91: 479-489, 1997.
31. Reed, J. Cytochrome c: can't live with it, can't live without it. Cell, 91: 559-562, 1997.
32. Nicholson, D., Ali, A., Thornberry, N., Vaillancourt, J., Ding, C., Gallant, M., Gareau, Y., Griffin, P., Labelle, M., Lazebnick, Y., Munday, N., Raju, S., Smulson, M., Yamin, T-T., Yu, V., and Miller, D. Identification and inhibition of the ICE/ CED-3 protease necessary for mammalian apoptosis. Nature (Lond.). 376: 37-43, 1995.
33. Petit, P. X., Goubern, M., Diolez, P., Susin, S. A., Zamzami, N., and Kroemer, G. Disruption of the outer mitochondrial membrane as a result of large amplitude swelling: the impact of irreversible permeability transition. FEBS Lett., 426: 111-116, 1998.
34. Hockenbery, D., Zutter, M., Mickey, W., Nahm, M., and Korsmeyer, S. Bcl-2 protein is topographically restricted in tissue characterized by apoptotic cell death. Proc. Natl. Acad. Sci. USA, 88: 6961-6995, 1991.
35. Cardillo, M., Berchem, G., Tarkington, M. A., Krajewski, S., Krajewski, M., Reed, J. C., Tehan, T., Ortega, L., Lage, J., and Gelmann, E. P. Resistance to apoptosis and up-regulation of Bcl-2 in benign prostatic hyperplasia after androgen deprivation. J. Urol., 158: 212-216, 1997.
36. Colombel, M., Symmans, F., Gil, S., O'Toole, K., Chopin, D., Benson, M., Olsson, C., Korsmeyer, S., and Buttyan R. Detection of the apoptosis suppressing oncoprotein bcl-2 in hormone refractory human prostate cancers. Am. J. Pathol., 143: 390-400, 1993.
37. McDonnell, T. J., Troncoso, P., Brisbay, S. M., Logothetis, C., Chang, L. W. K., Hsieh, J-T., Tu, S-M., and Campbell, M. L. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res., 52: 6940-6944, 1992.
38. Moul, J. W., Bettencourt, M. C., Sesterhenn, I. A., Mostofi, F. K., McLeod, D. G., Srivastava, S., and Bauer, J. J. Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer. Surgery (St. Louis), 120: 159-166, 1996.
39. Bauer, J. J., Sesterhenn, I. A., Mostofi, F. K., McLeod, D. G., Srivastava, S., and Moul, J. W. Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localised prostate cancer. J. Urol., 156: 1511-1516, 1996.
40. Bubendorf, L., Sauter, G., Moch, H., Jordan, P., Blochlinger, A., Gasser, T. C., and Mihatsch, M. J. Prognostic significance of Bcl-2 in clinically localized prostate cancer. Am. J. Pathol., 148: 1557-1565, 1996.
41. McDonnell, T. J., Navone, N. M., Troncoso, P., Pisters, L. L., Conti, C., von Eschenbach, A. C., Brisbay, S., and Logothetis, C. J. Expression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen-independent prostate cancer. J. Urol., 157: 569-574, 1997.
42. Guinan, P., Didomenico, D., Brown,J., Shaw, M., Sharifi, R., Ray, V., Shott, S., and Rubenstein, M. The effect of androgen deprivation on malignant and benign prostate tissue. Med. Oncol. (Lond.), 14: 145-152, 1997.
43. McConkey, D. J., Greene, G., and Pettaway, C. A. Apoptosis resistance increases with metastatic potential in cells of the human LNCaP prostate carcinoma line. Cancer Res., 56: 5594-5599, 1996.
44. Berchem, G. J., Bosseler, M., Sugars, L. Y., Voeller, H. J., Zeitlin, S., and Gelmann, E. P. Androgens induce resistance to bcl-2-mediated apoptosis in LNCaP prostate cancer cells. Cancer Res., 55: 735-738, 1995.
45. L function upstream of the CED-3-like apoptotic proteases. J. Biol. Chem., 271: 4573-4576, 1996.
46. Thompson, C. Apoptosis in the pathogenesis and treatment of disease. Science (Washington DC), 267: 1456-1462, 1995.
47. Loddick, S., Mackenzie, A., and Rothwell, N. An ICE inhibitor, z-VAD-DCB, attenuates ischaemic brain damage in the rat. Neuropeptides. 7: 1465-1468, 1996.
48. Hara, H., Friedlander, R., Gagliardini, V., Ayata, C., Fink, K., Huang, Z., Shimizu-Sasamata, M., Yaun, J., and Moskowitz, M. Inhibition of interleukin 1 β converting enzyme family proteases reduces ischemic and excitotoxic neuronal damage. Proc. Natl. Acad. Sci. USA. 94: 2007-2012, 1997.
49. Endres, M., Namura, S., Shimizu-Sasamata, M., Waeber, C., Zhang, L., Gomez-Isla, T., Hyman, B. T., and Moskowitz, M. A. Attenuation of delayed neuronal death after mild focal ischemia in mice by inhibition of the caspase family. J. Cereb. Blood Flow Metab., 18: 238-247, 1998.
50. Yaoita, H., Ogawa, K., Maehara, K., and Maruyama, Y. Attenuation of ischemia/ reperfusion injury in rats by a caspase inhibitor. Circulation, 97: 276-281, 1993.
51. Geng, Y. J. Regulation of programmed cell death or apoptosis in atherosclerosis. Heart Vessels. 12 (Suppl.). 76-80, 1997.
52. Yu, J., Sena-Esteves, M., Paulus, W., Breakfield, X., and Reeves, S. Retroviral delivery and tetracycline-dependent expression of IL-1 β-converting enzyme (ICE) in a rat glioma model provides controlled induction of apoptotic death in tumor cells. Cancer Res., 56: 5423-5427, 1996.
53. Kondo, S., Tanaka, Y. Kondo, Y., Ishizaka, Y., Hitomi, M., Haqqi, T., Liu, J., Barnett, G. H., Alnemri, E. S., and Barna, B. P. Retroviral transfer of CPP32β gene into malignant gliomas in vitro and in vivo. Cancer Res., 58: 962-967, 1998.
54. Miura, M., Zhu, H., Rotello, R., Hartwieg, E . and Yuan, J. Induction of apoptosis in fibroblasts by IL-1 β-converting enzyme, a mammalian homolog of the C. elegans cell death gene ced-3. Cell, 75: 653-660, 1993.
55. Wang, L., Miura, M., Bergeron, L., Zhu, H., and Yuan, J. Ich-I, an Ice/ced-3-related gene, encodes both positive and negative regulators of programmed cell death. Cell. 78: 739-750, 1994.
56. Srinivasula, S., Ahmad, M., MacFarlane, M., Huang, Z. L., Fernandez-Alnemri, T., and Alnemri, E, Generation of constitutively active recombinant caspases-3 and -6 by rearrangement of their subunit. J Biol. Chem., 273: 10107-10111, 1998.
57. Munday, N., Vaillancourt, J., Ali, A., Casano, F., Miller, D., Molineaux, S., Yaminm T., and Nicholson, D. Molecular cloning of ICErel-II and ICErel-III, members of the ICE/CED-3 family of cystcine proteases. J. Biol. Chem., 270: 15870-15876, 1995.
58. Hawkins, C., Uren, A., Häcker, G., Medcalf, R., and Vaux, D. Inhibition of interleukin 1 β-converting enzyme-mediated apoptosis of mammalian cells by baculovirus IAP. Proc. Natl. Acad. Sci. USA, 93: 13786-13790, 1996.